Piper Sandler raised the firm’s price target on Hims & Hers to $39 from $35 and keeps a Neutral rating on the shares. The firm notes that after-hours share reaction signals that investors need more certainty to be comfortable here, even when the Q1 report looks solid. Specifically, management reiterated their full year sales outlook, but this is despite delivering a nice Q1 beat and the new Wegovy partnership. Management also laid out an ambitious longer-term plan, creating a challenging show-me story for themselves, Piper adds. That said, margins are expanding nicely, and this is still a name delivering stronger financial performance than others in the firm’s space.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Buy Rating on Hims & Hers Health: Growth Potential in Weight Loss Segment and Future Revenue Targets
- Hims & Hers Health: Balancing Impressive Growth with Emerging Challenges – A Hold Recommendation
- Sell Rating for Hims & Hers Health Amid Growth Challenges and Market Uncertainties
- Hims & Hers price target raised to $30 from $25 at Citi
- Hims & Hers Stock (HIMS) Falls as Cautious Outlook Blurs Massive Revenue Growth